1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Boston Scientific's Single-Use Duodenoscope Hits European Markets After US Clearance

After getting the greenlight to sell the Exalt D single-use duodenoscopes in the US, Boston Scientific has received a CE mark for the device in Europe. The first of its kind, the surgical diagnostic device is intended to help reduce risks of infections.

Sep 16, 2019 Fremont / CA / USA - Boston Scientific office buildings in Silicon Valley; Boston Scientific Corporation is a manufacturer of medical devices used in interventional medical specialties

A month after getting approval in the US, Boston Scientific Corp.’s Exalt D single-use duodenoscope is ready for the European market as well. The company received a CE mark for the device, which is intended to drastically reduce the number of infections acquired through multiple use duodenoscopes.

Exalt D is first and only CE-marked and FDA-cleared single-use disposable duodenoscope on the market. It was also granted Breakthrough Device Designation from the FDA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.

Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&D

 
• By Marion Webb

Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 
• By Natasha Barrow

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By Marion Webb

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

More from Policy & Regulation